Webcast Keryx Biopharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference (Live) 02/09/10 at 2:00 p.m. ET

Corporate Profile Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonst... More >> Featured Report   2008 10-K

Stock Quote KERX (Common) Exchange NASDAQ (US Dollar) Price $2.27 Change (%)   0.19 (7.72%) Volume 1,067,822 Data as of 02/08/10 4:00 p.m. ET Minimum 20 minute delay Refresh quote Receive E-mail Alerts

Recent News

Date Title   02/03/10 Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 02/02/10 Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 01/29/10 Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 01/27/10 Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer

Upcoming Events

Date Title 02/09/10 2:00 p.m. ET Keryx Biopharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference Location New York, NY

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.